<DOC>
	<DOC>NCT00162136</DOC>
	<brief_summary>The purpose of this study is to determine the dose limiting toxicities, minimum tolerated dose and recommended dose for Phase II studies.</brief_summary>
	<brief_title>Clinical Study of Ixabepilone Administered as a 24 Hour Infusion in Patients With Solid Malignancies.</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<criteria>confirmed diagnosis of a primary solid tumor measurable or nonmeasurable disease progressive disease men and women greater or equal to 18 years of age. women of child bearing potential who are not using birth control women who are pregnant or breast feeding women with a positive pregnancy test on enrollment patients with brain metastasis prior treatment with Ixabepilone known history of human immunodeficiency virus (HIV)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>